AUTHORS
Adam J. Kanack, PhD, Avinash Kumar Singh, PhD2, Ganesh Raman, MD3, Emily Armstrong, BS4, Livia Hegerova, MD5, Lindsay Hammons, MD6, David Garcia I, MD7, Bin Ma, PhD8, Noah Splinter, MS9, Bansi P. Savaliya, MD10, Ajit Singh, PhD11, Damon E Houghton, MD, MS12, Anand Pabmanabhan, MBBS, PhD13
AFFILIATIONS
1 Mayo Clinic, Phoenix, Arizona, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 University of Washington, Seattle, Washington, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 University of Washington, Seattle, Washington, United States
6 University of Washington, Seattle, Washington, United States
7 University of Washington, Seattle, Washington, United States
8 Rapid Novor, Inc., Kitchener, Ontario, Canada
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 The Hormel Institute, University of Minnesota, Austin, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Monoclonal gammopathy of thrombotic significance (MGTS) is a recently described thrombophilia in which a monoclonal antibody contributes to otherwise unexplained thrombotic disease. Although previously reported cases have involved platelet factor 4 (PF4)-directed antibodies, we investigated thrombotic disease in two patients with monoclonal gammopathies whose monoclonal antibodies induced PF4-independent, FcγRIIA-dependent platelet activation.
Methods: Serum and purified IgG from a 61-year-old man (Patient 1) with IgG1 kappa monoclonal gammopathy of undetermined significance (MGUS), recurrent venous and arterial thrombotic complications, and thrombocytopenia were evaluated using P-selectin expression assays, platelet-binding flow cytometry, and recombinant FcγRIIA (CD32A) binding assays. FcγRIIA dependence was tested with two independent blocking monoclonal antibodies (IV.3 and II.3). The roles of Fc glycans and intact IgG architecture were assessed using PNGase F treatment and F(ab′)2, Fab, and Fc fragments. The patient monoclonal antibody was de novo sequenced, transiently expressed in CHO cells, and subjected to G2S2 Fc-glycan remodeling. Preparations were characterized by LC-ESI-QTOF mass spectrometry, size-exclusion chromatography, mass photometry, and reducing and nonreducing SDS-PAGE. Longitudinal serum samples and a sequence-defined recombinant IgG3 lambda monoclonal antibody from a second patient with cerebrovascular thrombotic events were tested as independent support for this phenotype.
Results: Patient 1 had a five-year history of recurrent extensive portomesenteric thrombosis and deep vein thrombosis/pulmonary embolism despite multiple antithrombotic therapies. Antigen-based anti-PF4 assays were negative, and serotonin release assay results were indeterminate because activation was not inhibited by high-dose unfractionated heparin. Purified Patient 1 IgG strongly activated platelets independently of PF4. Platelet binding and activation were nearly abolished by IV.3 and II.3, identifying FcγRIIA as a required proximal receptor. Intravenous immunoglobulin (IVIG) fully inhibited activation in buffer and attenuated activation after patient IgG was reconstituted into IgG-depleted donor serum. PNGase F treatment eliminated FcγRIIA binding, platelet binding, and platelet activation. F(ab′)2, Fab, and Fc fragments failed to reproduce intact IgG binding, supporting a requirement for Fc-glycan-sensitive intact antibody architecture and consistent with FcγRIIA cross-linking. Untreated recombinant Patient 1 monoclonal IgG showed limited platelet binding and activation, whereas G2S2-transglycosylated recombinant IgG markedly increased platelet binding and restored activation to levels similar to serum-derived IgG. Heavy-chain mass profiles of native and recombinant antibodies differed before but converged after PNGase F treatment, supporting a contribution of Fc-associated post-translational differences without identifying a single pathogenic glycoform. Mass photometry, size-exclusion chromatography, and SDS-PAGE provided orthogonal evidence of abnormal monoclonal IgG architecture in platelet-activating preparations. Serum obtained from Patient 2 at two time points four years apart and the sequence-defined recombinant IgG3 lambda antibody reproduced PF4-independent, FcγRIIA-sensitive platelet activation and FcγRIIA binding. In Patient 1, one dose of IVIG near-normalized the platelet count. Plasma-cell-directed therapy with daratumumab, bortezomib, and dexamethasone was associated with suppression of the monoclonal protein, normalization of the platelet count, and resolution of recurrent thrombosis.
Conclusions: These data identify a PF4-independent, FcγRIIA-dependent mechanistic subtype of MGTS in which abnormal monoclonal IgG architecture, influenced by Fc-associated glycosylation, promotes FcγRIIA engagement and platelet activation. Sequence-defined recombinant antibodies and longitudinal studies in an independent patient support monoclonal-antibody causality, cross-patient reproducibility, and persistence of this phenotype. Recognition of this mechanism may inform diagnosis in selected patients with recurrent thrombosis, thrombocytopenia, monoclonal gammopathy, and indeterminate functional HIT testing, while providing a mechanistic rationale for treatment with IVIG and plasma-cell-directed therapy.
DISCLOSURES
Adam J. Kanack, PhD: Mayo Clinic - Patents & Royalties